The Costa Rican healthcare system is a success story. According to the Social Progress Index for 2019, Cost Rica’s social indicators — including health outcomes — are the highest in Latin America and, even though Costa Rica is a developing country, are in the top 40 in the world.
Read More
This issue draws insights about health challenges and opportunities from multiple countries. Together, the articles offer insightful pathways to seizing robust opportunities for building stronger healthcare systems. A thread that links these articles is the need for organizational innovations that break down national and international silos in health and healthcare. This is a challenging task, but one fully within the competence of existing healthcare and life sciences policy and commerce.
Looking ahead, please stay tuned for our special issue in December on bipartisan solutions to U.S. healthcare reform. Read more
“Regi”, aka Regina E. Herzlinger, is the Nancy McPherson Professor of Business Administration at Harvard Business School and author of bestselling trade books on healthcare. “Regi’s ‘Innovating in Health Care’ Cases”, a regular HMPI feature, highlights teaching materials that focus on innovating across healthcare.
Our highlighted case in this issue, “Apple Health Records”, offers one step toward feasible integration, based on commercial innovation in electronic data systems. Read more
Amid all the talk about disruption and disruptors, little is offered to executives on how to respond to a disruptor, or even on how to become a disruptor. So how do disruptors work, and what do disruptors mean to healthcare?
Read more
Physician leadership training may be the key to bridging the discrepancy between healthcare spending and health outcomes. But training must go beyond the traditional focus on intellectual competencies.
Read more
Poor quality drugs are a global crisis posing a significant threat to the management of patients with non-communicable diseases. We document the prevalence of poor-quality drugs at the retail level in Lagos, Nigeria.
Read more
Generic and biosimilar drugs now comprise more than 90% of prescriptions and provide discipline on U.S. pharmaceutical prices. The challenge is reinforcing the norms and rules of competition in the bio-pharmaceutical industry.
Read more